Targeting myeloid cells by disrupting the CCL2/CCR2 axis, which regulates monocyte and macrophage recruitment to the tumor microenvironment, can limit the infiltration of pro-tumorigenic myeloid cells and enhance anti-tumor immune responses in experimental gliomas. This evidence concerns the gene CCL2 and central nervous system cancer.